References
- Fisher B, Redmond CK, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen in chemotherapy in primary breast cancer. J Clin Oncol 1983: 1(4): 227–41
- Baum M, et al. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years by Nolvadex Adjuvant Trial Organization. Lancet 1983: 1(8319): 257–62
- Baum M, Brinkley DM, Dossett JA, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983: 2(8347): 450
- Ribeiro G, Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res) 1983: 286(6368): 827–30
- Kaufmann M, et al. Risk adapted adjuvant chemo-hormonal therapy in operable nodal positive breast cancer. Gynecologic Adjuvant Breast Cancer Group (GABG). In: Jones SE, Salmon SE, eds. Adjuvant therapy of cancer IV. New York: Grune & Stratton. 1984: 369–78
- Kaufmann M, et al. Adjuvant postoperative treatment in postmenopausal women with node negative (N -) and node positive (N +) breast cancer. International Conference on Adjuvant Therapy of Cancer IV. Tucson: 1984 Mar 21–24 (Abstr P29)
- Treatment of early breast cancer. (Editorial) Lancet 1984: 2(8413): 1193
- Hubay CA, Gordon NH, Crowe JP, et al. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up. Surgery 1984: 96(1): 61–72
- Cummings FJ, Gray R, et al. Double-blind adjuvant therapy with tamoxifen versus placebo in patients older than 65 years with stage II breast cancer. Proc Am Soc Clin Oncol 1984: 3: 125
- Pritchard KI, Meakin JW, et al. A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. In: Jones. Salmon, eds,5 pp 339–47
- Palshof T, Mouridsen HT, et al. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. In: Mouridsen HT. Palshof T. eds. Breast cancer: experimental and clinical aspects. Elmsford, NY: Pergamon Press. 1980: 183–7
- Palshof T. Adjuvant endocrine therapy of primary operable breast cancer. A clinical trial of antiestrogen, estrogen and placebo to pre-and postmenopausal patients: five-year results including rate of recurrence, survival and correlation to estrogen receptor status. Third EORTC Breast Cancer Working Conference. Amsterdam: 1983 Apr 27–29: 1
- Rose C, Thorpe SM, Mouridsen HT, et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Treat 1983: 3(1): 77–84
- Margreiter R, et al. Adjuvant tamoxifen for early breast cancer: first analysis of the Austrian multi-centre trial. Thirteenth International Congress and Chemotherapy. Vienna: 1983 Aug 28-Sep 2: Supplement: 53–6
- Rivkin SE, Knight WA, et al. Adjuvant chemotherapy and hormonal therapy for operable breast cancer with positive axillary nodes. Proc Am Assoc Cancer Res 1984: 25: 181
- Wallgren A, Barral E, et al. Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones. Salmon, eds,5 pp 331–7
- Ludwig Breast Cancer Study Group. Adjuvant therapy for postmenopausal women with operable breast cancer, parts I & II. In: Jones. Salmon, eds,5 pp 379–404
- Bonadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985: 3(2): 259–75